Genotype and vascular phenotype linked by catecholamine systems

Circulation

Volumn 117, Issue 4, 2008, Pages 458-461

  Goldstein, David S ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Catecholamines; Editorials; Nervous system; Norepinephrine; Sympathetic; Tyramine; Vasoconstriction; Veins

Indexed keywords

3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; C REACTIVE PROTEIN; CATECHOLAMINE; NORADRENALIN TRANSPORTER; TYRAMINE; ADRENERGIC RECEPTOR STIMULATING AGENT;

ADRENERGIC STIMULATION; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CATECHOLAMINE METABOLISM; EDITORIAL; GENOTYPE; METABOLIC SYNDROME X; NEUROCHEMISTRY; NEUROENDOCRINE SYSTEM; PATHOPHYSIOLOGY; PHENOTYPE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPATHETIC NERVE; ADRENERGIC SYSTEM; BLOOD VESSEL; DRUG EFFECT; HUMAN; NOTE; PHYSIOLOGY;

BLOOD VESSELS; CATECHOLAMINES; GENOTYPE; HUMANS; PHENOTYPE; SYMPATHETIC NERVOUS SYSTEM; SYMPATHOMIMETICS; TYRAMINE;

EID: 41049089266     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.745737     Document Type: Editorial

References (35)

1. Fung MM, Nguyen C, Mehtani P, Salem RM, Perez B, Thomas B, Das M, Schork NJ, Mahata SK, Ziegler MG, O'Connor DT. Genetic variation within adrenergic pathways determines in vivo effects of presynaptic stimulation in humans. Circulation. 2008;117:517-525.
2. Vincent S, Robertson D. The broader view: catecholamine abnormalities. Clin Auton Res. 2002;12(suppl 1):I44-I49.
3. Lindmar R, Loffelholz K, Muscholl E. Differences between tyramine and dimethylphenylpiperazine in the Ca±±-dependency and in the temporary course of noradrenaline release from the isolated rabbit heart [in German]. Experientia. 1967;23:933-934.
4. Chubb IW, De Potter WP, De Schaepdryver AF. Tyramine does not release noradrenaline from splenic nerve by exocytosis. Naunyn Schmiedebergs Arch Pharmacol. 1972;274:281-286.
5. Langeloh A, Trendelenburg U. The mechanism of the 3H-noradrenaline releasing effect of various substrates of uptake1: role of monoamine oxidase and of vesicularly stored 3H-noradrenaline. Naunyn Schmiedebergs Arch Pharmacol. 1987;336:611-620.
6. Trendelenburg U. Carrier-mediated outward transport of noradrenaline from adrenergic varicosities. Pol J Pharmacol Pharm. 1990;42:515-520.
7. Kurz T, Richardt G, Seyfarth M, Schomig A. Nonexocytotic noradrenaline release induced by pharmacological agents or anoxia in human cardiac tissue. Naunyn Schmiedebergs Arch Pharmacol. 1996;354:7-16.
8. Goldstein DS, Holmes C. Metabolic fate of the sympathoneural imaging agent 6-[18F]fluorodopamine in humans. Clin Exper Hypertens. 1997;19:155-161.
9. Goldstein DS, Eisenhofer G, Stull R, Folio CJ, Keiser HR, Kopin IJ. Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Invest. 1988;81:213-220.
10. Eldadah BA, Pacak K, Eisenhofer G, Holmes C, Kopin IJ, Goldstein DS. Cardiac uptake-1 inhibition by high circulating norepinephrine levels in patients with pheochromocytoma. Hypertension. 2004;43:1227-1232.
11. Fischer JE, Horst WD, Kopin IJ. Beta-hydroxylated sympathomimetic amines as false neurotransmitters. Br J Pharmacol Chemother. 1965;24:477-484.
12. Mattiasson I, Mattiasson B, Hood B. Uptake and efflux of noradrenaline from platelets: a model system for neurogenic mechanisms in essential hypertension. Clin Sci. 1979;57:225s-227s.
13. Ferrier C, Cox H, Esler M. Elevated total body noradrenaline spillover in normotensive members of hypertensive families. Clin Sci. 1993;84:225-230.
14. Grossman E, Rea RF, Hoffman A, Goldstein DS. Yohimbine increases sympathetic nerve activity and norepinephrine spillover in normal volunteers.Am J Physiol. 1991;260:R142-R147.
15. Neumeister A, Geraci M, Belfer A, Goldman D, Holmes C, Bonne O, Alim T, Lawson W, Luckenbaugh DA, Charney DS, Goldstein DS. Alpha-2C adrenergic receptor gene regulation of sympathetic neuronal and adrenomedullary hormonal function in humans. Pharmacogenet Genom. 2005;13:143-149.
16. Miller JW, Streeten DH. Vascular responsiveness to norepinephrine in sympathicotonic orthostatic intolerance. J Lab Clin Med. 1990;115:549-558.
17. Sicuteri F, Del Bianco PL, Anselmi B. Morphine abstinence and serotonin supersensitivity in man: analogies with the mechanism of migraine? Psychopharmacology. 1979;65:205-209.
18. Blauw GJ, van Brummelen P, Bruning T, van Zwieten PA. Local hemodynamic effects of serotonin and ketanserin in healthy subjects: studies in the forearm. J Cardiovasc Pharmacol. 1988;11:S41-S43.
19. Mendlowitz M, Naftchi NE, Tuckman J, Gitlow SE, Wolf RL. The effect of tyramine on the digital circulation in normotensive and hypertensive subjects. Dis Chest. 1967;52:709-714.
20. Cardillo C, Kilcoyne CM, Quyyumi AA, Cannon RO, 3rd, Panza JA. Decreased vasodilator response to isoproterenol during nitric oxide inhibition in humans. Hypertension. 1997;30:918-921.
21. Eisenach JH, Clark ES, Charkoudian N, Dinenno FA, Atkinson JL, Fealey RD, Dietz NM, Joyner MJ. Effects of chronic sympathectomy on vascular function in the human forearm. J Appl Physiol. 2002;92:2019-2025.
22. Goldstein DS, Eisenhofer G, Kopin IJ. Clinical catecholamine neurochemistry: a legacy of Julius Axelrod. Cell Mol Neurobiol. 2006;26:695-702.
23. Goldstein DS, McCarty R, Polinsky RJ, Kopin IJ. Relationship between plasma norepinephrine and sympathetic neural activity. Hypertension. 1983;5:552-559.
24. Bianchetti MG, Minder I, Beretta-Piccoli C, Meier A, Weidmann P. Effects of tyramine on blood pressure and plasma catecholamines in normal and hypertensive subjects. Klin Wochenschr. 1982;60:465-470.
25. Goldstein DS, Eisenhofer G, Kopin IJ. Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther. 2003;305:800-811.
26. Eisenhofer G, Esler MD, Meredith IT, Dart A, Cannon RO III, Quyyumi AA, Lambert G, Chin J, Jennings GL, Goldstein DS. Sympathetic nervous function in human heart as assessed by cardiac spillovers of dihydroxyphenylglycol and norepinephrine. Circulation. 1992;85:1775-1785.
27. Jacob G, Gamboa A, Diedrich A, Shibao C, Robertson D, Biaggioni I. Tyramine-induced vasodilation mediated by dopamine contamination: a paradox resolved. Hypertension. 2005;46:355-359.
28. Rosenmeier JB, Fritzlar SJ, Dinenno FA, Joyner MJ. Exogenous NO administration and alpha-adrenergic vasoconstriction in human limbs. J Appl Physiol. 2003;95:2370-2374.
29. Jie K, van Brummelen P, Vermey P, Timmermans PB, van Zwieten PA. Modulation of noradrenaline release by peripheral presynaptic alpha 2-adrenoceptors in humans. J Cardiovasc Pharmacol. 1987;9:407-413.
30. Masuo K, Katsuya T, Sugimoto K, Kawaguchi H, Rakugi H, Ogihara T, Tuck ML. High plasma norepinephrine levels associated with beta2-adrenoceptor polymorphisms predict future renal damage in nonobese normotensive individuals. Hypertens Res. 2007;30:503-511.
31. Wessel J, Moratorio G, Rao F, Mahata M, Zhang L, Greene W, Rana BK, Kennedy BP, Khandrika S, Huang P, Lillie EO, Shih PA, Smith DW, Wen G, Hamilton BA, Ziegler MG, Witztum JL, Schork NJ, Schmid-Schonbein GW, O'Connor DT. C-reactive protein, an 'intermediate phenotype' for inflammation: human twin studies reveal heritability, association with blood pressure and the metabolic syndrome, and the influence of common polymorphism at catecholaminergic/ betaadrenergic pathway loci. J Hypertens. 2007;25:329-343.
32. Charkoudian N, Joyner MJ, Sokolnicki LA, Johnson CP, Eisenach JH, Dietz NM, Curry TB, Wallin BG. Vascular adrenergic responsiveness is inversely related to tonic activity of sympathetic vasoconstrictor nerves in humans. J Physiol. 2006;572:821-827.
33. Rao F, Zhang L, Wessel J, Zhang K, Wen G, Kennedy BP, Rana BK, Das M, Rodriguez-Flores JL, Smith DW, Cadman PE, Salem RM, Mahata SK, Schork NJ, Taupenot L, Ziegler MG, O'Connor DT. Tyrosine hydroxylase, the rate-limiting enzyme in catecholamine biosynthesis: discovery of common human genetic variants governing transcription, autonomic activity, and blood pressure in vivo. Circulation. 2007;116:993-1006.
34. Rao F, Wen G, Gayen JR, Das M, Vaingankar SM, Rana BK, Mahata M, Kennedy BP, Salem RM, Stridsberg M, Abel K, Smith DW, Eskin E, Schork NJ, Hamilton BA, Ziegler MG, Mahata SK, O'Connor DT. Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation. 2007;115(17):2271-2281.
35. Goldstein DS. Adrenaline and the Inner World: An Introduction to Scientific Integrative Medicine. Baltimore, Md: Johns Hopkins University Press; 2006.